Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,268.50 | 10.00 | 0.11% |
| CAC 40 | 8,123.91 | 7.24 | -0.09% |
| DAX 40 | 24,870.56 | 62.52 | -0.25% |
| Dow JONES (US) | 49,412.40 | 313.69 | 0.64% |
| FTSE 100 | 10,172.23 | 23.38 | 0.23% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,601.36 | 100.11 | 0.43% |
| Nikkei 225 | 53,333.54 | 448.29 | 0.85% |
| NZX 50 Index | 13,510.88 | 50.14 | 0.37% |
| S&P 500 | 6,950.23 | 34.62 | 0.50% |
| S&P/ASX 200 | 8,941.60 | 14.90 | 0.17% |
| SSE Composite Index | 4,139.90 | 7.30 | 0.18% |